Heather McKenzie is a Senior Editor at BioSpace, specializing in the field of life sciences. With a keen interest in the latest advancements in biotechnology and pharmaceuticals, Heather covers topics related to drug development, gene therapy, FDA approvals, and emerging startups in the industry. Her articles provide insights into the ever-evolving landscape of the life sciences sector.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Heather's coverage is predominantly focused on the healthcare and pharmaceutical industry, with a specific emphasis on FDA approvals, gene therapy, CRISPR technology, drug development, Alzheimer's disease, and CNS diseases. Her articles heavily cite data and press releases.
Given Heather’s focus on citing data and press releases in her articles about healthcare and pharmaceuticals, she may be interested in receiving pitches from experts who can provide statistical analysis or insights based on solid scientific evidence related to these topics. Pitches offering access to exclusive data or early access to research findings could also be appealing.
Heather does not appear to have a specific geographic focus but rather seems to cover global developments within the healthcare and pharmaceutical industry.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Heather-Mckenzie
Novartis, Gilead, Roche and Takeda commit to new partners in a spate of mid-sized collaborations this week. Meanwhile, Applied Therapeutics' stock tanks 80% after govorestat is denied approval, Intra-Cellular Therapies seeks to expand Caplyta into major depressive disorder and the FDA investigates the safety of bluebird bio's Skysona.
SMU faces Clemson for the ACC championship title and a spot in the playoffs Saturday Dec. 7 at 8:00 p.m.
The darlings of the weight loss and diabetes spaces, GLP-1 receptor agonists have shown promise against Alzheimer's in recent studies—with Phase III results expected next year from Novo Nordisk.
By: Heather Mckenzie, Jef Akst, Annalee Armstrong
GSK, Gilead and Arcellx, Vertex and more present new data at the American Society of Hematology annual meeting just as sickle cell therapies Casgevy and Lyfgenia have a new outcomes-based payment model; Eli Lilly and Novo Nordisk pump new funds into manufacturing; and AbbVie makes a Cerevel…
This year has seen smashing clinical successes and gut-wrenching failures, opening new markets for some biopharma firms while sending others back to the drawing board.
Even as Biogen and Eisai's Leqembi and Eli Lilly's Kisunla slowly roll out onto the market, experts question the efficacy of these anti-amyloid antibodies and the amyloid hypothesis overall.
In this deep dive BioSpace explores the opportunities and challenges presented by the FDA’s accelerated approval program.
With the benefits of taxonomies increasingly recognised, efforts are under way to create standardisation among disparate initiatives.
Madrigal Pharmaceuticals, X4 Pharmaceuticals and Day One Biopharmaceuticals secured their maiden approvals this year in metabolic dysfunction-associated steatohepatitis, WHIM syndrome and pediatric low-grade glioma. Geron Corporation and ImmunityBio also notched wins.
This year saw lofty highs and devastating lows for neuroscience drug developers like Bristol Myers Squibb, Eli Lilly and AbbVie, following the predictable pattern of successes and failures that characterizes this space.
(833) 317-6278 
